455-84-5

Basic information

• Product Name: 4-FLUORO-3-METHYLBENZOYL CHLORIDE
• Synonyms: 4-FLUORO-M-TOLUOYL CHLORIDE;4-FLUORO-3-METHYLBENZOYL CHLORIDE;4-Fluoro-3-methylbenzoyl chloride, 97+%;4-Fluoro-3-methylbenzoyl;4-Fluoro-3-methylbenzoyl chloride 98%;4-Fluoro-3-methylbenzoylchloride98%;5-(Chlorocarbonyl)-2-fluorotoluene
• CAS NO: 455-84-5
• Molecular Formula: C₈H₆ClFO
• Molecular Weight: 172.58
• EINECS: -0
• Product Categories: Acid Halides;Carbonyl Compounds;Organic Building Blocks
• Mol File: 455-84-5.mol

Chemical Properties

• Boiling Point: 129-133 °C17 mm Hg(lit.)
• Flash Point: 208 °F
• Appearance: /
• Density: 1.215 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.158mmHg at 25°C
• Refractive Index: n20/D 1.5320(lit.)
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), DMSO (Sparingly)
• Sensitive: Moisture Sensitive
• Stability: Moisture Sensitive
• BRN: 1936532
• CAS DataBase Reference: 4-FLUORO-3-METHYLBENZOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUORO-3-METHYLBENZOYL CHLORIDE(455-84-5)
• EPA Substance Registry System: 4-FLUORO-3-METHYLBENZOYL CHLORIDE(455-84-5)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39-45-27
• RIDADR: UN 3265 8/PG 2
• WGK Germany: 3
• TSCA: N
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 455-84-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Fluoro-3-methylbenzoyl chloride is used as a key intermediate in the synthesis of various medicinal compositions. Its application is primarily focused on its ability to inhibit p38MAP kinases and/or TNF-α production, which are crucial factors in the development of pain and inflammation.
As a p38MAP Kinase Inhibitor:
4-Fluoro-3-methylbenzoyl chloride is used as a p38MAP kinase inhibitor for the development of pain relief medications. p38MAP kinases are enzymes that play a significant role in the regulation of cellular responses to stress and inflammation. By inhibiting these enzymes, the compound can help reduce the severity of pain and inflammation associated with various conditions.
As a TNF-α Production Inhibitor:
4-Fluoro-3-methylbenzoyl chloride is also used as an inhibitor of TNF-α production. TNF-α, or tumor necrosis factor-alpha, is a cytokine involved in systemic inflammation and is a key player in the pathogenesis of various inflammatory diseases. By inhibiting TNF-α production, the compound can potentially alleviate the symptoms of these diseases and contribute to the development of anti-inflammatory medications.

InChI:InChI=1/C8H6ClFO/c1-5-4-6(8(9)11)2-3-7(5)10/h2-4H,1H3

Upstream product

• 403-15-6 4-fluoro-3-methyl-benzoic acid 

Downstream Products

• 136007-05-1 2-[Bis-(4-fluoro-3-methyl-phenyl)-methyl]-6-chloro-4-methyl-phenol 
• 136007-06-2 2-[Bis-(4-fluoro-3-methyl-phenyl)-methyl]-4,6-dichloro-phenol 
• 110705-96-9 (4R,6S)-6-{2-[Bis-(4-fluoro-3-methyl-phenyl)-methyl]-6-chloro-4-methyl-phenoxymethyl}-4-hydroxy-tetrahydro-pyran-2-one 
• 110705-95-8 (4R,6S)-6-{2-[Bis-(4-fluoro-3-methyl-phenyl)-methyl]-4,6-dichloro-phenoxymethyl}-4-hydroxy-tetrahydro-pyran-2-one 
• 136007-35-7 (4R,6S)-6-{2-[Bis-(4-fluoro-3-methyl-phenyl)-methyl]-6-chloro-4-methyl-phenoxymethyl}-4-(tert-butyl-diphenyl-silanyloxy)-tetrahydro-pyran-2-ol 
• 110724-01-1 ((2S,4R)-2-{2-[Bis-(4-fluoro-3-methyl-phenyl)-methyl]-6-chloro-4-methyl-phenoxymethyl}-6-methoxy-tetrahydro-pyran-4-yloxy)-tert-butyl-diphenyl-silane 
• 136007-36-8 (4R,6S)-6-{2-[Bis-(4-fluoro-3-methyl-phenyl)-methyl]-4,6-dichloro-phenoxymethyl}-4-(tert-butyl-diphenyl-silanyloxy)-tetrahydro-pyran-2-ol 
• 110724-00-0 ((2S,4R)-2-{2-[Bis-(4-fluoro-3-methyl-phenyl)-methyl]-4,6-dichloro-phenoxymethyl}-6-methoxy-tetrahydro-pyran-4-yloxy)-tert-butyl-diphenyl-silane 
• 110705-91-4 (4R,6S)-6-{2-[Bis-(4-fluoro-3-methyl-phenyl)-methyl]-6-chloro-4-methyl-phenoxymethyl}-4-(tert-butyl-diphenyl-silanyloxy)-tetrahydro-pyran-2-one 
• 110705-90-3 (4R,6S)-6-{2-[Bis-(4-fluoro-3-methyl-phenyl)-methyl]-4,6-dichloro-phenoxymethyl}-4-(tert-butyl-diphenyl-silanyloxy)-tetrahydro-pyran-2-one 
• 136006-45-6 Sodium; (3R,5S)-6-{2-[bis-(4-fluoro-3-methyl-phenyl)-methyl]-6-chloro-4-methyl-phenoxy}-3,5-dihydroxy-hexanoate 
• 834895-47-5 3-(3-methoxy-4-pyrrolidinophenyl)-3-phenyl-3H-naphtho[2,1-b]pyran 

Relevant articles and documents

Palladium-Catalyzed C-H Trifluoroethoxylation of N-Sulfonylbenzamides

The trifluoroethyl aryl ethers are important motifs in drug molecules. However, a report devoted specifically to the study of transition-metal-catalyzed C-H trifluoroethoxylation has not been reported to date. A protocol of Pd(II)-catalyzed o-C-H trifluor

SUBSTITUTED TRIAZOLES AND THEIR USE FOR TREATMENT AND/OR PREVENTION NEUROLOGICAL AND PSYCHIATRIC DISORDERS

This invention relates to compounds of formula (I), their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

New carboxylic acid amides, the preparation thereof and their use as medicaments

The present invention relates to new substituted carboxylic acid amides of general formula wherein A, B and R1 to R5 are defined as in claim 1, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.

Synthesis and photochromic properties of substituted 3H-naphtho[2,1-b] pyrans

The synthesis and spectroscopic properties of novel 3H-naphtho[2,1-b]pyrans are described. Subtle variation of the colour of the photo-generated merocyanine dyes derived from these naphthopyrans can be accomplished by controlling the steric interactions between a terminal pyrrolidine donor group and a proximal substituent.

NOVEL CARBOXAMIDES FOR USE AS XA INHIBITORS

The invention relates to the novel substituted carboxamides of general formula (I), wherein A, B and R1 to R5 are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures and salts thereof, especially the physiologically salts thereof with inorganic or organic acids or bases, which have valuable properties. The inventive compounds have an antithrombotic effect and are factor Xa inhibitors.

JNK INHIBITOR

The present invention relates to a c-Jun N-terminal kinase inhibitor containing an azole compound (I) substituted by a nitrogen-containing aromatic group having substituent(s)(except a compound represented by the formula: ) or a salt thereof or a prodrug thereof.

Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC

Deacetylation of uridyldiphospho-3-O-(R-hydroxydecanoyl)-N-acetylglucosamine by LpxC is the first committed step in the Pseudomonas aeruginosa biosynthetic pathway to lipid A; homologous enzymes are found widely among Gram-negative bacteria. As an essential enzyme for which no inhibitors have yet been reported, the P. aeruginosa LpxC represents a highly attractive target for a novel antibacterial drug. We synthesized several focused small-molecule libraries, each composed of a variable aromatic ring, one of four heterocyclic/spacer moieties, and a hydroxamic acid and evaluated the LpxC inhibition of these compounds against purified P. aeruginosa enzyme. To ensure that the in vitro assay would be as physiologically relevant as possible, we synthesized a tritiated form of the specific P. aeruginosa glycolipid substrate and measured directly the enzymatically released acetate. Several of our novel compounds, predominantly those having fluorinated substituents on the aromatic ring and an oxazoline as the heterocyclic moiety, demonstrated in vitro IC50 values less than 1 μM. We now report the synthesis and in vitro evaluation of these P. aeruginosa LpxC inhibitors.